Baxter

Baxter International, Inc. engages in the provision of a portfolio of essential renal and hospital products, including acute and chronic dialysis, sterile IV solutions, infusion systems and devices, parenteral nutrition therapies, premixed and oncolytic injectable, bio surgery products and anesthetics, drug reconstitution systems and pharmacy automation, software, and services. It operates through the following segment: Americas, Europe, Middle East and Africa (EMEA), Asia-Pacific (APAC), and Hillrom. The Americas, EMEA, and APAC segments offer a portfolio of essential healthcare products. The Hillrom segment provides digital and connected care solutions and collaboration tools, including smart bed systems, patient monitoring and diagnostic technologies, respiratory health devices and advanced equipment for the surgical space. The company was founded by Davis Baxter in 1931 and is headquartered in Deerfield, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Baxter reports robust Q4 sales, eyes growth amid operational challenges

Baxter International's Q4 2022 performance reflects strong sales growth and strategic actions to enhance agility and market responsiveness.
While facing challenges such as lower-than-expected earnings and supply chain constraints, the company is focused on cost reduction and operational improvements.
Opportunities lie in R&D investments, cost synergies from the Hillrom integration, and improving backlog and backorders, positioning Baxter for future growth.
Analysts' concerns about operating margins and financial outlook for 2023 highlight the need for continued efficiency measures and strategic planning.

Baxter beats Q1 expectations, plans spin-off for strategic clarity

Baxter's Q1 performance exceeded expectations with sales growth in key segments and adjusted EPS surpassing guidance.
The company is progressing well with its strategic initiatives, including the spin-off of Renal Care and new operating model.
Challenges in legacy businesses and soft hospital spending highlight areas for improvement, while opportunities lie in new product launches and margin enhancement strategies.
Overall, Baxter's focus on innovation, operational efficiency, and market trends positions it for long-term success and growth.

Baxter exceeds Q2 expectations, eyes growth amid strategic actions

Baxter's Q2 2023 performance showcased resilience and adaptability in a dynamic healthcare market, with strategic actions underway to drive operational efficiency and growth.
The company's focus on innovation, safety, and market responsiveness positions it well for future success, despite challenges such as pending divestitures and market uncertainties.
With a strong performance, growth opportunities in key segments, and operational improvements driving margin expansion, Baxter is navigating challenges to capitalize on future growth prospects.

Baxter beats Q3 expectations, eyes growth through strategic initiatives

Baxter's Q3 2023 performance exceeded expectations, with a focus on strategic priorities and the upcoming Kidney Care segment separation.
The company's strengths lie in maintaining market share, operational efficiencies, and maximizing shareholder value through financial analysis.
Challenges include renegotiating contracts, rising energy costs, and achieving organic growth amidst market dynamics.
Opportunities for Baxter include growth through cost improvements, margin programs, and product launches in 2024.

Baxter surpasses Q4 expectations, eyes growth amid inflation challenges

Baxter's Q4 2023 performance exceeded expectations, driven by growth in key segments and strategic initiatives, setting the stage for continued success in 2024.
Despite challenges like inflation and flat growth in certain segments, Baxter's focus on margin improvement, debt management, and growth strategies positions the company for future resilience.
With a strong outlook for 2024, Baxter aims to capitalize on opportunities for growth, margin improvement, and market expansion, supported by a solid financial foundation and strategic priorities.

Baxter surpasses Q1 expectations with focus on innovation and growth

Baxter's Q1 2024 performance exceeded expectations, driven by strong sales growth and focus on innovation, despite challenges in certain segments and geographies.
The company's strategic strengths lie in diverse growth drivers, strong segment margins, and geographic expansion successes, positioning it for continued success.
Addressing challenges in underperforming segments and markets, along with seizing opportunities for improvement and expansion, will be crucial for Baxter's future growth.
With a clear focus on innovation, margin expansion, and shareholder value maximization, Baxter aims to navigate challenges and capitalize on growth prospects for sustained success.

Baxter exceeds Q2 expectations, plans Kidney Care separation for growth

Baxter International's Q2 2024 earnings call highlighted robust performance, strategic initiatives, and a positive outlook for sales growth and earnings per share.
The company's focus on margin improvement, innovation, and operational efficiency positions it well for sustained growth and shareholder value creation.
While facing challenges in certain segments and external factors, Baxter's proactive approach and strong fundamentals offer opportunities for future expansion and success.
Investors can look forward to Baxter's continued commitment to driving growth, expanding margins, and delivering innovative healthcare solutions.

Baxter reports solid Q3 performance amidst challenges and growth opportunities

Baxter International demonstrated resilience in Q3 2024 with sales growth and earnings exceeding expectations despite challenges.
The company's focus on operational efficiency, cost containment, and strategic divestitures positions it well for future growth.
Challenges from Hurricane Helene impact and Kidney Care separation are being addressed with a clear vision for sustained performance.
Opportunities for growth and margin expansion underscore Baxter's commitment to delivering value to shareholders and patients.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Baxter International, Inc. engages in the provision of a portfolio of essential healthcare products including acute and chronic dialysis therapies, sterile intravenous (IV) solutions, infusion systems and devices, parenteral nutrition therapies, inhaled anesthetics, generic injectable pharmaceuticals, surgical hemostat and sealant products, surgical equipment, smart bed systems, patient monitoring and diagnostic technologies, and respiratory health devices. It operates through the following segments: Americas, Europe, Middle East and Africa (EMEA), Asia-Pacific (APAC), and Hillrom. The Americas, EMEA, and APAC segments offer a portfolio of essential healthcare products. The Hillrom segment provides digital and connected care solutions and collaboration tools, including smart bed systems, patient monitoring and diagnostic technologies, respiratory health devices, and equipment for the surgical space. The company was founded by Davis Baxter in 1931 and is headquartered in Deerfield, IL.

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Morgan Stanley 20th Annual Global Healthcare Conference on Wednesday, September 14, 2022. Jay Saccaro, Baxter's chief financial officer, is scheduled to present at 10:35 a.m. Eastern Time. The live webcast of Baxter's presentation can be accessed at www.baxter.com and will be available for replay through March 13, 2023. About Baxter Every day, millions of patients and caregivers

Baxter to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

Baxter boasts a broad portfolio of medically necessary products and therapies, and its brand strength is a key advantage. The company's products can be found in just about any healthcare facility from hospitals to nursing homes and beyond in over 100 countries.

Baxter's Shares Are Starting To Look Cheap

Baxter's (BAX) second-quarter results reflect the robust performance of the Medication Delivery business unit and Hilrom's businesses.

Baxter (BAX) Q2 Earnings Miss Estimates, Hilrom Adds $715 M

Investors weren't happy with the company's Q2 update.

Why Baxter International Stock Is Tumbling Today

Baxter International Inc. (NYSE:BAX ) Q2 2022 Results Earnings Conference Call July 28, 2022 8:30 AM ET Company Participants Clare Trachtman - Vice President, Investor Relations José Almeida - Chairman, President and Chief Executive Officer James Saccaro - ​Executive Vice President and Chief Financial Officer Conference Call Participants Robbie Marcus – J.P. Morgan Vijay Kumar - Evercore ISI Pito Chickering - Deutsche Bank Travis Steed - Bank of America Securities Joanne Wuensch - Citigroup Larry Biegelsen - Wells Fargo Joshua Jennings - Cowen and Company Operator Good morning, ladies and gentlemen, and welcome to Baxter International's Second Quarter 2022 Earnings Conference Call.

Baxter International Inc. (BAX) CEO José Almeida on Q2 2022 Results - Earnings Call Transcript

Baxter (BAX) delivered earnings and revenue surprises of -1.14% and 3.73%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Baxter International (BAX) Misses Q2 Earnings and Revenue Estimates

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the second quarter of 2022. “Baxter's diverse, durable portfolio of essential healthcare products powers our business, even amid unprecedented macroeconomic headwinds,” said José (Joe) E. Almeida, chairman, president and chief executive officer. “While we continue to navigate a dynamic near-term landscape, our recent combination with Hillrom is fueling the next phase of ou

Baxter Reports Second-Quarter 2022 Results

Baxter's (BAX) second-quarter results are likely to reflect growth in its Medication Delivery and BioPharma Solutions businesses. Hillrom's products are likely to have boosted sales

Baxter (BAX) to Report Q2 Earnings: What's in the Offing?

Cummins

Marsh & McLennan

Realty Income Corp

Phillips 66

Daily Dividend Report: Cummins, Marsh McLennan, Baxter International, Realty Income, Phillips 66

DEERFIELD, Ill.--(BUSINESS WIRE)---- $BAX--Baxter International Inc. (NYSE:BAX), a global medtech leader, today released its 2021 Corporate Responsibility Report, demonstrating how the company is progressing toward its 2030 Corporate Responsibility Commitment and Goals. The report highlights the continued progress Baxter has made to advance environmental, social and governance (ESG) performance across its operations and philanthropic programs. “Baxter's unwavering dedication to responsible corporate cit

Baxter Details Progress Toward Environmental, Social and Governance (ESG) Priorities in Annual Corporate Responsibility Report

Alnylam Pharmaceuticals

Biogen

Boston Scientific

Cardinal Health

Gilead Sciences

Johnson & Johnson

Karuna Therapeutics Inc

Medtronic

Mirati Therapeutics

Natera

Roche Holding AG

Stryker

Vertex Pharmaceuticals

SPDR S&P Biotech ETF

If you have the discipline to think long-term as an investor, this is the time to take advantage of the steep discounts on great biotechnology companies.

Seven reasons the beleaguered biotech sector is now a ‘buy'

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its second-quarter 2022 financial results on Thursday, July 28, 2022 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://conferencingportals.com/event/EmxweYhQ to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter's website at www.baxter.com

Baxter to Host Second-Quarter 2022 Financial Results Conference Call for Investors

Investors continue to be optimistic about Baxter (BAX) due to its strong product portfolio and regulatory clearances.

Here's Why You Should Retain Baxter (BAX) Stock For Now

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Goldman Sachs 43rd Annual Global Healthcare Conference on Tuesday, June 14, 2022. José (Joe) Almeida, Baxter's chairman and chief executive officer, is scheduled to present at 10:40 a.m. Pacific Time. The live webcast of Baxter's presentation can be accessed at www.baxter.com and will be available for replay through June 13, 2023. About Baxter Every day, millions of patients and

Baxter to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference

Avery Dennison

Expeditors International of Washington

First Merchants

Houlihan Lokey

Haverty Furniture Companies

LCI Industries

ManpowerGroup

Monro

PepsiCo

QUALCOMM

Universal Forest Products

Advanced Drainage Systems

Watts Water Technologies

All stocks have at least five fiscal years of dividend growth history and come from the U.S. Dividend Champions List. They have an average increase of 12.4% and a median increase of 10.3%. I've tracked 282 increases in 2022, 211 increases in Q1 2022, and 71 in Q2.

14 Upcoming Dividend Increases Including A Soon To Be King

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will showcase its ongoing trajectory of transformation and growth at its 2022 Investor Conference, being held today in Glenview, Ill. The company's executive leadership team will highlight Baxter's strategy to continue creating compelling value for patients, clinicians and investors through leading-edge innovation, market expansion, operational efficiency and other vital growth levers. This is Baxte

Baxter Highlights Business Strategies and Innovation at 2022 Investor Conference

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will host an investor conference on Wednesday, May 25, 2022 in Glenview, Ill. Chairman and CEO Joe Almeida and other members of Baxter's management team will provide a closer look at the company's growth strategy, innovation pipeline and longer term financial outlook. The investor conference will feature an innovation hall displaying product and therapy advancements from Baxter's pipeline beginning

Baxter to Host 2022 Investor Conference

AbbVie

Amgen

Quest Diagnostics

Humana

Merck

Zoetis

As market conditions remain rocky, adding high-quality healthcare stocks to your portfolio may be a great way to play defense. The post 7 Defensive Dividend Healthcare Stocks to Buy Now appeared first on InvestorPlace.

7 Defensive Dividend Healthcare Stocks to Buy Now

I've been on a crusade for the past 2 weeks to highlight investable dividend-paying quality business as we're experiencing a market drop. My work takes me now to revisit the company Baxter International, a quality business in the medical supply field. I wrote about the company several months ago.

Baxter: Some Real 'Buy' Appeal

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medtech company, today announced an increase in the company's quarterly cash dividend to a rate of $0.29 per share of common stock. This represents an approximately 3.5% increase over the previous quarterly dividend rate of $0.28 per share. Baxter's Board of Directors declared the dividend payable on July 1, 2022, to stockholders of record as of June 3, 2022. The indicated annual dividend rate is now $1.16

Baxter Increases Dividend and Declares Quarterly Dividend

Chesapeake Energy

Devon Energy

Diamondback Energy

Packaging Corp of America

After years of a low interest rate environment, many investors have turned to equities, not only for the growth potential but also for solid and dependable dividends that help to provide an income stream.

Red-Hot Energy Companies Among 5 ‘Strong Buy' Stocks With Expected Dividend Hikes This Week

Baxter's (BAX) first-quarter results reflect robust performance across four of its business units.

Baxter (BAX) Q1 Earnings and Revenues Surpass Estimates

Baxter International Inc. (NYSE:BAX ) Q1 2022 Results Conference Call April 28, 2022 8:30 AM ET Company Participants Clare Trachtman - VP, IR Joe Almeida - Chairman, CEO Giuseppe Accogli - COO Jay Saccaro - CFO Conference Call Participants Drew Ranieri - Morgan Stanley Danielle Antalffy - SVB Leerink Joanne Wuensch - Citi Larry Biegelsen - Wells Fargo Matt Miksic - Credit Suisse Pito Chickering - Deutsche Bank Robbie Marcus - JP Morgan Travis Steed - Bank of America Vijay Kumar - Evercore ISI Operator Good morning, ladies and gentlemen, and welcome to Baxter International's First Quarter 2022 Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded by Baxter and is copyrighted material.

Baxter International Inc. (BAX) CEO Joe Almeida on Q1 2022 Results - Earnings Call Transcript

Baxter (BAX) delivered earnings and revenue surprises of 16.25% and 1.12%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Baxter International (BAX) Surpasses Q1 Earnings and Revenue Estimates

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the first quarter of 2022. “Our positive momentum in the first quarter of 2022 was fueled by the diversity and durability of our medically essential product portfolio – dynamics that have further strengthened with our recent acquisition of Hillrom,” said José (Joe) E. Almeida, chairman, president and chief executive officer. “As we continue to navigate the impact of COVID-

News for Baxter Stock (BAX)